Loading...
Loading...
VYNE| Name | Value |
|---|---|
| Revenues | 76.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 76.0K |
| Operating Expense | 6,908.0K |
| Operating I/L | -6,832.0K |
| Other Income/Expense | 680.0K |
| Interest Income | 0.0K |
| Pretax | -6,152.0K |
| Income Tax Expense | 37.0K |
| Net Income/Loss | -6,188.0K |
VYNE Therapeutics Inc. is a pharmaceutical company specializing in the development of therapeutics for immuno-inflammatory conditions. The company's product pipeline includes FCD105, a topical combination foam for moderate-to-severe acne vulgaris, and FMX114, a tofacitinib-based treatment for mild-to-moderate atopic dermatitis. Additionally, VYNE is working on VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin conditions, and VYN202, which consists of selective BET inhibitor compounds. These products are aimed at addressing unmet medical needs and generating revenue through commercialization and sales in the pharmaceutical market.
